Author(s):
Daimah Wirdatus Sanaun Harahap, Retnosari Andrajati, Santi Purna Sari, Diah Handayani, Mohd Makmor Bakry
Email(s):
andrajati@farmasi.ui.ac.id
DOI:
10.52711/0974-360X.2026.00686 
Address:
Daimah Wirdatus Sanaun Harahap1, Retnosari Andrajati1*, Santi Purna Sari1, Diah Handayani2, Mohd Makmor Bakry3
1Clinical Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia
2Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Universitas Indonesia Hospital, Depok 16424, West Java, Indonesia
3Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia
*Corresponding Author
Published In:
Volume - 19,
Issue - 10,
Year - 2026
ABSTRACT:
Tuberculosis is one of the leading causes of death from infections worldwide. Indonesia ranks second globally in terms of the highest number of TB cases. The number of tuberculosis cases in Depok City has been increasing annually (2019-2022). Drug-resistant tuberculosis (DR-TB) services at University of Indonesia Hospital (RSUI) are the first of their kind in Depok City. Specialised counseling has been demonstrated to improve compliance among pulmonary tuberculosis patients. The aim of this study was to compare the effects of pharmacist counseling and leaflet media on improving compliance in patients with DR-TB at the RSUI. A quasi-experimental with a non-equivalent control group was employed in the research design. Patients were divided into two groups: the intervention group with leaflet media with pharmacist counseling (48 patients) and the intervention group with leaflet media only (48 patients). The study duration was from February to May 2024, with a two-month gap between pre-test and post-test. The intervention outcomes were measured as adherence score using the MMAS-8 questionnaire. The effectiveness analysis of the interventions on compliance showed that the intervention group with leaflet media with pharmacist counseling had a 0.489 (0.398 – 0.602) times chance of improving compliance, which was not statistically significant (p-value >0.05) compared to the group with leaflet media alone. The conclusion of this study indicates that the addition of pharmacist counseling on leaflet media did not further improve the compliance among DR-TB patients. Additional studies employing randomized controlled trials are required to assess the efficacy of these interventions.
Cite this article:
Daimah Wirdatus Sanaun Harahap, Retnosari Andrajati, Santi Purna Sari, Diah Handayani, Mohd Makmor Bakry. A Comparison of the Effects of Pharmacist Counseling and Leaflet Media on Medication Adherence in Drug-Resistant Tuberculosis (DR-TB) Patients at the University of Indonesia Hospital. Research Journal Pharmacy and Technology. 2026;19(10):4925-2. doi: 10.52711/0974-360X.2026.00686
Cite(Electronic):
Daimah Wirdatus Sanaun Harahap, Retnosari Andrajati, Santi Purna Sari, Diah Handayani, Mohd Makmor Bakry. A Comparison of the Effects of Pharmacist Counseling and Leaflet Media on Medication Adherence in Drug-Resistant Tuberculosis (DR-TB) Patients at the University of Indonesia Hospital. Research Journal Pharmacy and Technology. 2026;19(10):4925-2. doi: 10.52711/0974-360X.2026.00686 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-10-62
REFERENCES:
1. World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023. Available from: https://iris.who.int/. Accessed 2023 Nov 8.
2. Ministry of Health of the Republic of Indonesia. Tuberculosis control program report 2022. Jakarta: Directorate General of Disease Prevention and Control; 2023.
3. World Health Organization. Tuberculosis profile: Indonesia. 2023. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/. Accessed 2023 Nov 8.
4. Ministry of Health of the Republic of Indonesia. Treatment adherence in tuberculosis. 2022. Available from: https://yankes.kemkes.go.id/view_artikel/637/kepatuhan-pengobatan-pada-tbc. Accessed 2024 Jul 10.
5. Sajel S, Saranya P. Quality of life in patients experiencing diabetic foot ulcer: a cross-sectional study in a clinical pharmacist’s perspective. Res J Pharm Technol. 2017; 10(1): 219-22. doi:10.5958/0974-360X.2017.00046.4.
6. Thanmayi G, Shanmugasundaram P, Geetha P. Role of clinical pharmacist in improving patients’ compliance including risk factors among tuberculosis patients. Res J Pharm Technol. 2017; 10(9): 2945-8. doi:10.5958/0974-360X.2017.00521.2.
7. Archana S, Ram M. A prospective study on assessment of medication adherence toward antihypertensive medications. Res J Pharm Technol. 2017; 10(11): 3779-82. doi:10.5958/0974-360X.2017.00685.0.
8. Maheshwari P, Nirenjen S, Bergin RVB, Pavithradevi M, Arun S, Shanmugasundaram P. Improvement of patient compliance through patient counselling in patients with diabetic foot ulcer. Res J Pharm Technol. 2018; 11(6): 2248-50. doi:10.5958/0974-360X.2018.00416.X.
9. Islahudin F, Hasan SZ. Medication adherence and satisfaction among patients in Malaysia. Res J Pharm Technol. 2019;12(3):1051-4. doi:10.5958/0974-360X.2019.00173.2.
10. Pribadi P, Kristina SA, Syahlani SP, Satibi. Empirical test of pharmacist-patient relationship model in hospital pharmacy practice: Indonesia context. Res J Pharm Technol. 2019; 12(10): 4623-7. doi:10.5958/0974-360X.2019.00795.9.
11. Pristianty L, Faturrohmah A, Rahmadani B. Effects of behavior factors on patients’ adherence to antihypertensive medicine at Pucang Sewu clinic Surabaya. Res J Pharm Technol. 2020; 13(4): 1623-6. doi:10.5958/0974-360X.2020.00294.2.
12. Mathew AC, Aneesa MV, Rehman A, Suresh D, Suriyaprakash TNK, Joy SP. Assessment of medication adherence patterns and causes of non-adherence in long-term therapies in a tertiary hospital. Res J Pharm Technol. 2020; 13(5): 2420-6. doi:10.5958/0974-360X.2020.00434.5.
13. Gowri PM, Bhuvaneswari G, Manoj C, Varatharajan R, Subhashini, Jomcy, Epsimal. Knowledge and associated factors of DOTS defaulters among tuberculosis clients. Res J Pharm Technol. 2018;11(6):2313-6. doi:10.5958/0974-360X.2018.00429.8.
14. Shaik RA, Jaffer S, Fatima SH. Prevalence of adverse drug reactions, drug interactions, and comorbidities in tuberculosis patients. Res J Pharm Technol. 2021; 14(7): 3911-5. doi:10.52711/0974-360X.2021.00679.
15. Krasniqi S, Jakupi A, Daci A, Tigani B, Jupolli-Krasniqi N, Pira M, et al. Tuberculosis treatment adherence in Kosovo. Tuberc Res Treat. 2017; 2017: 1-8. doi:10.1155/2017/4850324.
16. Asgedom SW, Teweldemedhin M, Gebreyesus H. Prevalence of multidrug-resistant tuberculosis and associated factors in Ethiopia: a systematic review. J Pathog. 2018; 2018: 1-8. doi:10.1155/2018/7104921.
17. Berlowitz DR, Foy CG, Kazis LE, Bolin L, Conroy LB, Fitzpatrick P, et al. Impact of intensive blood pressure therapy on patient-reported outcomes: SPRINT study. N Engl J Med. 2017; 377: 733-44.
18. Bress AP, Bellows BK, King J, Hess R, Beddhu S, Zhang Z, et al. Cost-effectiveness of intensive versus standard blood pressure control. N Engl J Med. 2017; 377: 745-55.
19. Oh AL, Makmor-Bakry M, Islahudin F, Wong ICK. Tuberculosis treatment interruption in Asia: systematic review and meta-analysis. BMJ Glob Health. 2023; 8(1). doi:10.1136/bmjgh-2022-010592.
20. Iskandar D, Suryanegara FDA, van Boven JFM, Postma MJ. Clinical pharmacy services for tuberculosis management: systematic review. Front Pharmacol. 2023; 14. doi:10.3389/fphar.2023.1186905.
21. Karuniawati H, Putra ON, Wikantyasning ER. Impact of pharmacist counseling and leaflet on adherence of pulmonary tuberculosis patients. Indian J Tuberc. 2019; 66(3): 364-9. doi:10.1016/j.ijtb.2019.02.015.
22. Laili FN, Octavia DR. Relationship between treatment adherence of drug-resistant tuberculosis and therapy outcomes. J Sains Kesehat. 2023. doi:10.25026/jsk.v5i5.1968.
23. Husnawati, Retnosari A, Herianto. Effect of counseling on tuberculosis drug therapy adherence in pulmonary TB patients. Maj Ilmu Kefarm. 2007; 6(2): 49-58.
24. Suiraoka IP, Supariasa IDN. Health education media. Yogyakarta: Graha Ilmu; 2012.
25. Universitas Indonesia Hospital. UI Hospital ranked among the world’s top 250 academic hospitals in 2023. Available from: https://rs.ui.ac.id/. Accessed 2024 Jul 6.
26. Universitas Indonesia Hospital. UI Hospital opens drug-resistant tuberculosis services. 2022. Available from: https://rs.ui.ac.id/. Accessed 2024 Jul 6.
27. Bhardwaj M, Shah KV. Demographic and clinical profile of multidrug-resistant tuberculosis in a tertiary hospital. IP Indian J Immunol Respir Med. 2021; 6(2): 80-5. doi:10.18231/j.ijirm.2021.018.
28. Jiang Y, Zhao X, Fan Z. CT imaging features of drug-resistant pulmonary tuberculosis using intelligence classification algorithm. Comput Intell Neurosci. 2022; 2022. doi:10.1155/2022/3141807.
29. Prasetya FA, Sugiri YJ, Sartono TR, Al Rasyid H. Factors affecting treatment success of short-term regimen for DR-TB patients. J Respirol Indones. 2022; 42(3): 192-200. doi:10.36497/jri.v40i3.360.
30. Bea S, Lee H, Kim JH, Jang SH, Son H, Kwon JW, et al. Adherence factors in drug-susceptible tuberculosis treatment. Front Pharmacol. 2021; 12. doi:10.3389/fphar.2021.625078.
31. Srinivasan G, Chaturvedi D, Verma D, Pal H, Khatoon H, Yadav D, et al. Depression and anxiety among drug-resistant tuberculosis patients. Indian J Tuberc. 2021; 68(4): 457-63. doi:10.1016/j.ijtb.2021.04.010.
32. Gebreweld FH, Kifle MM, Gebremicheal FE, et al. Factors influencing tuberculosis treatment adherence in Eritrea. J Health Popul Nutr. 2018; 37(1). doi:10.1186/s41043-017-0132-y.
33. Dogah E, Aviisah M, Kuatewo DAM, et al. Factors influencing adherence to tuberculosis treatment in Ghana. Tuberc Res Treat. 2021; 2021: 1-6. doi:10.1155/2021/6685039.
34. Nezenega ZS, Perimal-Lewis L, Maeder AJ. Factors influencing tuberculosis treatment adherence in Ethiopia: literature review. Int J Environ Res Public Health. 2020; 17(15): 1-12. doi:10.3390/ijerph17155626.
35. Fana TE, Ijeoma E, Sotana L. Knowledge, attitudes, and prevention practices of drug-resistant tuberculosis in South Africa. Tuberc Res Treat. 2019; 2019: 1-12. doi:10.1155/2019/8978021.
36. Vyawahare C, Mukhida S, Khan S, et al. Risk factors associated with drug-resistant pulmonary tuberculosis. Indian J Tuberc. 2023. doi:10.1016/j.ijtb.2023.07.007.
37. Hassani S, Mohammadi Shahboulagi F, Foroughan M, et al. Medication adherence in elderly tuberculosis patients: qualitative study. Can J Infect Dis Med Microbiol. 2023; 2023. doi:10.1155/2023/4056548.
38. Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Outcome of longer regimen MDR-TB treatment in West Java. PLoS One. 2021; 16(2). doi:10.1371/journal.pone.0246284.
39. Eliza D. Effectiveness of pharmacist-led telepharmacy interventions. [thesis]. Depok: Universitas Indonesia; 2023.
40. Tiberi S, Utjesanovic N, Galvin J, et al. Drug-resistant TB: epidemiology, diagnostics, and management. Int J Infect Dis. 2022; 124: S20-5. doi:10.1016/j.ijid.2022.03.026.
41. Chaliks R, Hartono R, Kamal SE, et al. COVID-19 pandemic and urban health issues. Urban Health. 2021; 3(1).
42. Endo Y, Jaramillo J, Yadav RPH. Barriers to treatment adherence in drug-resistant tuberculosis in the Philippines. Tuberc Res Treat. 2022; 2022: 1-11. doi:10.1155/2022/6466960.
43. Venkatesh U, Srivastava D, Srivastava A, Tiwari H. Epidemiological profile of MDR-TB in Uttar Pradesh, India. J Fam Med Prim Care. 2018; 7(3): 589. doi:10.4103/jfmpc.jfmpc_99_17.